Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2010

01.06.2010 | Original Article

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging

verfasst von: Till-Alexander Heusner, Sherko Kuemmel, Angela Koeninger, Monia E. Hamami, Steffen Hahn, Anton Quinsten, Andreas Bockisch, Michael Forsting, Thomas Lauenstein, Gerald Antoch, Alexander Stahl

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the study was to prospectively compare the diagnostic value of whole-body diffusion-weighted imaging (DWI) and FDG PET/CT for breast cancer (BC) staging.

Methods

Twenty BC patients underwent whole-body FDG PET/CT and 1.5-T DWI. Lesions with qualitatively elevated signal intensity on DW images (b = 800 s/mm2) were rated as suspicious for tumour and mapped to individual lesions and different compartments (overall 552 lesions). The apparent diffusion coefficient (ADC) value was determined for quantitative evaluation. Histopathology, MRI findings, bone scan findings, concordant findings between FDG PET/CT and DWI, CT follow-up scans and plausibility served as the standards of reference defining malignancy.

Results

According to the standards of reference, breasts harboured malignancy in 11, regional lymph nodes in 4, M1 lymph nodes in 3, bone in 7, lung in 2, liver in 3 and other tissues in 3 patients. On a compartment basis, the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for the detection of malignancies were 94, 99, 98, 97 and 98% for FDG PET/CT and 91, 72, 76, 50 and 96% for DWI, respectively. Of the lesions seen on DWI only, 348 (82%) turned out to be false-positive compared to 23 (11%) on FDG PET/CT. The average lesion ADC was 820 ± 300 with true-positive lesions having 929 ± 252 vs 713 ± 305 in false-positive lesions (p < 0.0001).

Conclusion

Based on these initial data DWI seems to be a sensitive but unspecific modality for the detection of locoregional or metastatic BC disease. There was no possibility to quantitatively distinguish lesions using ADC. DWI alone may not be recommended as a whole-body staging alternative to FDG PET(/CT). Further studies are necessary addressing the question of whether full-body MRI including DWI may become an alternative to FDG PET/CT for whole-body breast cancer staging.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.CrossRefPubMed
3.
Zurück zum Zitat Rubens RD. 7. Management of advanced breast cancer. Int J Clin Pract 2001;55:676–9.PubMed Rubens RD. 7. Management of advanced breast cancer. Int J Clin Pract 2001;55:676–9.PubMed
4.
Zurück zum Zitat Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1–22.CrossRefPubMed Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1–22.CrossRefPubMed
5.
Zurück zum Zitat Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545–51.CrossRefPubMed Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545–51.CrossRefPubMed
6.
Zurück zum Zitat Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215–29.CrossRefPubMed Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215–29.CrossRefPubMed
7.
Zurück zum Zitat Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010;73:294–9.CrossRefPubMed Dirisamer A, Halpern BS, Flöry D, Wolf F, Beheshti M, Mayerhoefer ME, et al. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010;73:294–9.CrossRefPubMed
8.
Zurück zum Zitat Hayashi M, Murakami K, Oyama T, Domeki Y, Hagiwara S, Katsumata D, et al. PET/CT supports breast cancer diagnosis and treatment. Breast Cancer 2008;15:224–30.CrossRefPubMed Hayashi M, Murakami K, Oyama T, Domeki Y, Hagiwara S, Katsumata D, et al. PET/CT supports breast cancer diagnosis and treatment. Breast Cancer 2008;15:224–30.CrossRefPubMed
9.
Zurück zum Zitat Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008;81:743–8.CrossRefPubMed Heusner TA, Freudenberg LS, Kuehl H, Hauth EA, Veit-Haibach P, Forsting M, et al. Whole-body PET/CT-mammography for staging breast cancer: initial results. Br J Radiol 2008;81:743–8.CrossRefPubMed
10.
Zurück zum Zitat Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215–22.CrossRefPubMed Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215–22.CrossRefPubMed
11.
Zurück zum Zitat Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36:1543–50.CrossRefPubMed Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36:1543–50.CrossRefPubMed
12.
Zurück zum Zitat Holdsworth SJ, Bammer R. Magnetic resonance imaging techniques: fMRI, DWI, and PWI. Semin Neurol 2008;28:395–406.CrossRefPubMed Holdsworth SJ, Bammer R. Magnetic resonance imaging techniques: fMRI, DWI, and PWI. Semin Neurol 2008;28:395–406.CrossRefPubMed
13.
Zurück zum Zitat Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622–35.CrossRefPubMed Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188:1622–35.CrossRefPubMed
14.
Zurück zum Zitat Vilanova JC, Barcelo J. Diffusion-weighted whole-body MR screening. Eur J Radiol 2008;67:440–7.CrossRefPubMed Vilanova JC, Barcelo J. Diffusion-weighted whole-body MR screening. Eur J Radiol 2008;67:440–7.CrossRefPubMed
15.
Zurück zum Zitat Barceló J, Vilanova JC, Riera E, Balliu E, Peláez I, Martí J, et al. Diffusion-weighted whole-body MRI (virtual PET) in screening for osseous metastases. Radiologia 2007;49:407–15. Spanish.CrossRefPubMed Barceló J, Vilanova JC, Riera E, Balliu E, Peláez I, Martí J, et al. Diffusion-weighted whole-body MRI (virtual PET) in screening for osseous metastases. Radiologia 2007;49:407–15. Spanish.CrossRefPubMed
16.
Zurück zum Zitat Nakanishi K, Kobayashi M, Nakaguchi K, Kyakuno M, Hashimoto N, Onishi H, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007;6:147–55.CrossRefPubMed Nakanishi K, Kobayashi M, Nakaguchi K, Kyakuno M, Hashimoto N, Onishi H, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007;6:147–55.CrossRefPubMed
17.
Zurück zum Zitat Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6:135–43.CrossRefPubMed Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6:135–43.CrossRefPubMed
18.
Zurück zum Zitat Bohlscheid A, Nuss D, Lieser S, Busch HP. Tumor search with diffusion-weighted imaging–first experience. Rofo 2008;180:302–9. German.PubMed Bohlscheid A, Nuss D, Lieser S, Busch HP. Tumor search with diffusion-weighted imaging–first experience. Rofo 2008;180:302–9. German.PubMed
19.
Zurück zum Zitat Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment–utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008;248:643–54.CrossRefPubMed Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment–utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008;248:643–54.CrossRefPubMed
20.
Zurück zum Zitat Szafer A, Zhong J, Anderson AW, Gore JC. Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed 1995;8:289–96.CrossRefPubMed Szafer A, Zhong J, Anderson AW, Gore JC. Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed 1995;8:289–96.CrossRefPubMed
21.
Zurück zum Zitat Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008;249:1017–25.CrossRefPubMed Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008;249:1017–25.CrossRefPubMed
22.
Zurück zum Zitat Nakayama T, Yoshida S, Fujii Y, Koga F, Saito K, Masuda H, et al. Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary. Nippon Hinyokika Gakkai Zasshi 2008;99:737–41. Japanese.PubMed Nakayama T, Yoshida S, Fujii Y, Koga F, Saito K, Masuda H, et al. Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary. Nippon Hinyokika Gakkai Zasshi 2008;99:737–41. Japanese.PubMed
23.
Zurück zum Zitat Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008;3:358–64.CrossRefPubMed Mori T, Nomori H, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008;3:358–64.CrossRefPubMed
24.
Zurück zum Zitat Nomori H, Mori T, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008;135:816–22.CrossRefPubMed Nomori H, Mori T, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008;135:816–22.CrossRefPubMed
25.
Zurück zum Zitat Kanauchi N, Oizumi H, Honma T, Kato H, Endo M, Suzuki J, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg 2009;35:706–10.CrossRefPubMed Kanauchi N, Oizumi H, Honma T, Kato H, Endo M, Suzuki J, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg 2009;35:706–10.CrossRefPubMed
26.
Zurück zum Zitat Keskek M, Balas S, Gokoz A, Sayek I. Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today 2006;36:1047–52.CrossRefPubMed Keskek M, Balas S, Gokoz A, Sayek I. Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today 2006;36:1047–52.CrossRefPubMed
27.
Zurück zum Zitat Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987;59:682–7.CrossRefPubMed Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987;59:682–7.CrossRefPubMed
28.
Zurück zum Zitat Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983;197:276–83.CrossRefPubMed Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 1983;197:276–83.CrossRefPubMed
29.
Zurück zum Zitat Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879–85.CrossRefPubMed Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879–85.CrossRefPubMed
30.
Zurück zum Zitat Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30:588–96.PubMed Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30:588–96.PubMed
31.
Zurück zum Zitat Komori T, Narabayashi I, Matsumura K, Matsuki M, Akagi H, Ogura Y, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007;21:209–15.CrossRefPubMed Komori T, Narabayashi I, Matsumura K, Matsuki M, Akagi H, Ogura Y, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007;21:209–15.CrossRefPubMed
32.
Zurück zum Zitat Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2009;72:381–7.CrossRefPubMed Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J. Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2009;72:381–7.CrossRefPubMed
33.
Zurück zum Zitat Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009;251:398–407.CrossRefPubMed Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009;251:398–407.CrossRefPubMed
34.
Zurück zum Zitat Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009;29:336–40.CrossRefPubMed Ono K, Ochiai R, Yoshida T, Kitagawa M, Omagari J, Kobayashi H, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009;29:336–40.CrossRefPubMed
35.
Zurück zum Zitat Luo JD, Liu YY, Zhang XL, Shi LC. Application of diffusion weighted magnetic resonance imaging to differential diagnosis of breast diseases. Ai Zheng 2007;26:168–71. Chinese.PubMed Luo JD, Liu YY, Zhang XL, Shi LC. Application of diffusion weighted magnetic resonance imaging to differential diagnosis of breast diseases. Ai Zheng 2007;26:168–71. Chinese.PubMed
36.
Zurück zum Zitat Lo GG, Ai V, Chan JK, Li KW, Cheung PS, Wong TT, et al. Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T. J Comput Assist Tomogr 2009;33:63–9.CrossRefPubMed Lo GG, Ai V, Chan JK, Li KW, Cheung PS, Wong TT, et al. Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T. J Comput Assist Tomogr 2009;33:63–9.CrossRefPubMed
37.
Zurück zum Zitat Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006;24:319–24.CrossRefPubMed Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging 2006;24:319–24.CrossRefPubMed
38.
Zurück zum Zitat Partridge SC. Future applications and innovations of clinical breast magnetic resonance imaging. Top Magn Reson Imaging 2008;19:171–6.CrossRefPubMed Partridge SC. Future applications and innovations of clinical breast magnetic resonance imaging. Top Magn Reson Imaging 2008;19:171–6.CrossRefPubMed
39.
Zurück zum Zitat Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Kikuchi K, et al. Comparison of breast cancer detection by diffusion-weighted magnetic resonance imaging and mammography. Radiat Med 2007;25:218–23.CrossRefPubMed Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Kikuchi K, et al. Comparison of breast cancer detection by diffusion-weighted magnetic resonance imaging and mammography. Radiat Med 2007;25:218–23.CrossRefPubMed
40.
Zurück zum Zitat Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009;22:104–13.CrossRefPubMed Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009;22:104–13.CrossRefPubMed
41.
Zurück zum Zitat Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med 2008;26:222–6.CrossRefPubMed Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med 2008;26:222–6.CrossRefPubMed
42.
Zurück zum Zitat Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 2008;28:1157–65.CrossRefPubMed Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 2008;28:1157–65.CrossRefPubMed
43.
Zurück zum Zitat Yili Z, Xiaoyan H, Hongwen D, Yun Z, Xin C, Peng W, et al. The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer 2009;9:18.CrossRefPubMed Yili Z, Xiaoyan H, Hongwen D, Yun Z, Xin C, Peng W, et al. The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer 2009;9:18.CrossRefPubMed
44.
Zurück zum Zitat Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360–85.CrossRefPubMed Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360–85.CrossRefPubMed
Metadaten
Titel
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging
verfasst von
Till-Alexander Heusner
Sherko Kuemmel
Angela Koeninger
Monia E. Hamami
Steffen Hahn
Anton Quinsten
Andreas Bockisch
Michael Forsting
Thomas Lauenstein
Gerald Antoch
Alexander Stahl
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1399-z

Weitere Artikel der Ausgabe 6/2010

European Journal of Nuclear Medicine and Molecular Imaging 6/2010 Zur Ausgabe